Download PDF

1. Company Snapshot

1.a. Company Description

Ercros, S.A. manufactures and sells basic chemicals, intermediate chemicals, and pharmaceuticals in Spain.It operates through three segments: Chlorine Derivatives, Intermediate Chemicals, and Pharmacy.The Chlorine Derivatives segment produces ammonia, bioplastics, caustic potash and soda, chlorine, chloroisocyanurates, dicalcium phosphate, dichloroethane, hydrochloric acid, hydrogen peroxide, potassium carbonate, PVC compounds, sodium chlorate and chlorite, sodium hypochlorite, and vinyl chloride monomers.


This segment's products are used as intermediates in other industrial processes to purify and treat drinking and waste water; treat and maintain swimming pool water; bleach fabrics and paper; produce solvents, detergents, and strippers; manufacture printing inks and coloring; to produce compound feed and in cooling equipment.The Intermediate Chemicals segment provides formaldehyde, glues and resins, molding powders, paraformaldehyde, pentaerythritol and dipentaerythritol, and sodium formate for manufacturing chipboards, and decorative laminates and plywoods, as well as resins, paints, and varnishes in the furniture and decoration industry; plugs and switches in the electrical components sector; and household, sanitary, and packaging materials in the textile tanning industry.The Pharmacy division engages in the production of raw materials and intermediate products from antibiotic, cholesterol-lowering, anti-ulcer, and anti-fungal agents.


This segment's products include amlodipine besylate, azithromycin, clarithromycin, erythromycins, famotidine, calcium and sodium fosfomycin, fosfomycin trometamol, and fusidic acid.The company is also involved in exporting activities.Ercros, S.A. was founded in 1817 and is headquartered in Barcelona, Spain.

Show Full description

1.b. Last Insights on ECR

Recent news suggests that Ercros, S.A. has been gaining attention from investors due to its growth prospects and high insider ownership. The company has been mentioned as one of the promising penny stocks to watch, with articles highlighting its potential for significant returns. Additionally, Ercros has been identified as a stock that may be trading below its estimated value, offering a strategic opportunity for investors. However, there is no information on recent earnings releases or any significant drivers that may have impacted the company's performance.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

European Growth Companies With Insider Confidence November 2025

Nov -28

Source:

Card image cap

European Growth Stocks With Significant Insider Ownership

Oct -30

Source:

Card image cap

October 2025's Top European Growth Stocks With High Insider Ownership

Oct -01

Source:

Card image cap

European Growth Stocks With Significant Insider Ownership

Sep -02

Source:

Card image cap

European Growth Companies With High Insider Ownership August 2025

Aug -04

Source:

Card image cap

Clarithromycin Market Analysis and Forecast 2025-2030, with Profiles of Ercros, Guobang Pharmaceutical, Zhejiang Nexchem Pharmaceutical, HEC Pharm, Alembic Pharmaceuticals, Kopran, SM Biomed, & more

Jun -30

Source:

Card image cap

European Penny Stocks To Watch In April 2025

Apr -17

Source:

Card image cap

March 2025's European Penny Stocks To Watch

Mar -19

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.85%)

6. Segments

Derivatives of Chlorine

Expected Growth: 0.8%

The 0.8 growth rate of Derivatives of Chlorine from Ercros, S.A. is driven by increasing demand from the water treatment industry, expansion into emerging markets, and strategic partnerships. Additionally, investments in R&D have improved production efficiency, reducing costs and increasing competitiveness. These factors have contributed to the steady growth of the segment.

Chemistry Intermediate

Expected Growth: 0.9%

Ercros' Chemistry Intermediate segment growth of 0.9 is driven by increasing demand for specialty chemicals, expansion into new markets, and strategic partnerships. Additionally, the company's focus on R&D and process optimization has improved production efficiency, leading to higher volumes and revenue growth.

Pharmacy

Expected Growth: 1.1%

Ercros, S.A.'s Pharmacy segment growth of 1.1% is driven by increasing demand for generic and specialty medicines, expansion into new markets, and strategic partnerships. Additionally, investments in digitalization and e-commerce platforms enhance customer experience, contributing to moderate growth.

7. Detailed Products

Chlorine

Ercros, S.A. produces chlorine through the electrolysis of sodium chloride, used as a disinfectant, sanitizer, and oxidizing agent in various industries such as water treatment, paper bleaching, and pharmaceuticals.

Caustic Soda

Ercros, S.A. produces caustic soda, also known as sodium hydroxide, used in various industries such as paper, textiles, and soap manufacturing, as well as in the production of detergents and cleaning products.

Chlorine Derivatives

Ercros, S.A. produces a range of chlorine derivatives, including chloroform, carbon tetrachloride, and perchloroethylene, used in various applications such as pharmaceuticals, agrochemicals, and refrigerants.

Intermediate Chemicals

Ercros, S.A. produces intermediate chemicals, including epichlorohydrin, used in the production of epoxy resins, and other specialty chemicals used in various industries.

Pharmaceutical Intermediates

Ercros, S.A. produces pharmaceutical intermediates, including APIs (Active Pharmaceutical Ingredients) and other specialty chemicals used in the production of pharmaceuticals.

8. Ercros, S.A.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Ercros, S.A. is medium due to the availability of alternative products in the market.

Bargaining Power Of Customers

The bargaining power of customers for Ercros, S.A. is high due to the concentration of customers in the market.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Ercros, S.A. is low due to the availability of multiple suppliers in the market.

Threat Of New Entrants

The threat of new entrants for Ercros, S.A. is medium due to the moderate barriers to entry in the market.

Intensity Of Rivalry

The intensity of rivalry for Ercros, S.A. is high due to the high competition in the market.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 25.82%
Debt Cost 3.95%
Equity Weight 74.18%
Equity Cost 8.30%
WACC 7.17%
Leverage 34.80%

11. Quality Control: Ercros, S.A. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Rokita

A-Score: 6.1/10

Value: 7.8

Growth: 3.6

Quality: 4.2

Yield: 10.0

Momentum: 2.0

Volatility: 9.0

1-Year Total Return ->

View Full Report
Stock-Card
Tessenderlo

A-Score: 5.0/10

Value: 7.8

Growth: 2.3

Quality: 3.1

Yield: 3.8

Momentum: 5.5

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
Robertet

A-Score: 4.8/10

Value: 3.5

Growth: 7.1

Quality: 6.0

Yield: 1.2

Momentum: 1.0

Volatility: 9.7

1-Year Total Return ->

View Full Report
Stock-Card
Zaklady Azotowe Pulawy

A-Score: 4.8/10

Value: 10.0

Growth: 3.0

Quality: 3.9

Yield: 1.9

Momentum: 3.5

Volatility: 6.3

1-Year Total Return ->

View Full Report
Stock-Card
Grupa Azoty Zaklady Chemiczne Police

A-Score: 3.3/10

Value: 7.5

Growth: 2.3

Quality: 1.6

Yield: 0.0

Momentum: 2.0

Volatility: 6.3

1-Year Total Return ->

View Full Report
Stock-Card
Ercros

A-Score: 3.1/10

Value: 9.4

Growth: 1.2

Quality: 2.6

Yield: 1.9

Momentum: 1.0

Volatility: 2.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

3.31$

Current Price

3.31$

Potential

-0.00%

Expected Cash-Flows